Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

Journal of Surgical Oncology

Volumn 93, Issue 7, 2006, Pages 585-592

  Grana, G ^a,b  

^a Department of Anesthesiology   (United States)

^b Cardiovascular Disease   (United States)

Author keywords

Anastrozole; Exemestane; Hormonal treatment; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FRACTURE; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; ISCHEMIA; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NIGHT SWEAT; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TRIAZOLES;

EID: 33744454916     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20564     Document Type: Review

References (28)

1. American Cancer Society: Cancer facts & figures 2005. http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
2. Group EBCTC: Tamoxifen for early breast cancer (Cochrane Review). In: "The Cochrane Library, Issue 4." Chichester, UK: John Wiley & Sons, Ltd, 2005.
3. Hendrix SL, McNeeley SG: Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann N Y Acad Sci 2001;949:243-250.
4. Mounts MJ, De Vries EG, Willemse PH, et al.: Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol 2001;97:855-856.
5. Bissett D, Davis JA, George WD: Gynaecological monitoring during tamoxifen therapy. Lancet 1994;344:1244.
6. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
7. Cutuli B, Petit J, Fricker J: Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: Occurrence of thromboembolic complications. Oncol Rep 1994;1:59-63.
8. Meier CR, Jick H: Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45:608-612.
9. Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
10. Fisher B, Dignam J, Bryant J, et al.: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
11. Thurlimann B, Keshaviah A, Coates AS, et al.: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
12. Rea D: Phase III randomized study of adjuvant exemestane versus adjuvant tamoxifen in postmenopausal women with early breast cancer. Protocol CRC-TU-TEAM. Available at: http://www.cancer.gov/clinicaltrials. Accessed January 14, 2004.
13. Jakesz R, Jonat W, Gnant M, et al.: Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
14. Boccardo F, Rubagotti A, Puntoni M, et al.: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-5147.
15. Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
16. Goss PE, Ingle JN, Martino S, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
17. Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 2004;350:1081-1092.
18. Howell A, on behalf of the ATAC Trialists' Group: The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer: Updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2005;88:S7.
19. Mouridsen HT: Exemestane following tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2004;22:3833-3834.
20. Peto R, Boreham J, Clarke M, et al.: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
21. Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-629.
22. Clemett D, Lamb HM: Exemestane: A review of its use in postmenopausal women with advanced breast cancer. Drugs 2000;59:1279-1296.
23. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-2016.
24. Punglia RS, Kuntz KM, Winer EP, et al.: Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 2005;23:5178-5187.
25. Cuzick J: Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 2005;23(16S):658.
26. Eiermann W, Paepke S, Appfelstaedt J, et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
27. Smith IE, Dowsett M, Ebbs SR, et al.: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: The IMPACT multicenter double blind randomized trial. J Clin Oncol 2005;23:5108-5117.
28. Jakesz R, Samonigg H, Greil R, et al.: Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005;23:527.